NRx Pharma shareholders approve stock issuance to Streeterville Capital

NRX Pharmaceuticals, Inc.

Stockholders approved issuance of common shares to Streeterville Capital, LLC under Nasdaq Listing Rule 5635(d).
Vote results: 38,338,555 for, 311,870 against, 373,843 abstentions.
Special meeting reconvened on March 3, 2023, with quorum present throughout.
Approval allows company to proceed with share issuance, potentially for financing or debt conversion.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

NRX Pharmaceuticals, Inc. shareholders approved Approval of issuance of shares of common stock to Streeterville Capital, LLC in accordance with Nasdaq Listing Rule 5635(d) at the 2023-03-03 meeting.

Outcome: passed
Meeting: 2023-03-03

Exact text from the filing

The Company’s stockholders approved approve the issuance of shares of common stock to Streeterville Capital, LLC in accordance with Nasdaq Listing Rule 5635(d). The results of the voting were as follows: Votes For Votes Against Abstentions 38,338,555 311,870 373,843

View on SEC.gov

Browse all shareholder votes →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950142-23-000586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.